Sanofi cleared to market Admelog mealtime insulin
PARIS — Sanofi has received Food and Drug Administration approval for Admelog, described as the first follow-on insulin lispro to help people with diabetes manage blood sugar levels at mealtime. Sanofi said Monday that Admelog (insulin lispro injection, 100 units/ml) will be available in both vials and the SoloStar pen, which is the most-used disposable
